News articles about WAVE Life Sciences (NASDAQ:WVE) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. WAVE Life Sciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.2513994161167 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of WAVE Life Sciences (NASDAQ:WVE) traded down 0.538% during mid-day trading on Thursday, reaching $23.125. 39,266 shares of the company’s stock were exchanged. WAVE Life Sciences has a 52-week low of $15.15 and a 52-week high of $40.15. The company’s 50-day moving average price is $22.78 and its 200 day moving average price is $21.20. The company’s market cap is $641.95 million.
WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.14). The firm had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.73 million. WAVE Life Sciences had a negative return on equity of 55.19% and a negative net margin of 3,375.12%. On average, equities research analysts predict that WAVE Life Sciences will post ($3.71) EPS for the current year.
Several research firms have recently weighed in on WVE. Zacks Investment Research upgraded shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. BidaskClub upgraded shares of WAVE Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $40.00 price target (down previously from $42.00) on shares of WAVE Life Sciences in a report on Thursday, August 10th. Finally, Mizuho set a $34.00 target price on shares of WAVE Life Sciences and gave the stock a “buy” rating in a report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $40.00.
TRADEMARK VIOLATION NOTICE: This report was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/10/12/wave-life-sciences-wve-receives-media-impact-score-of-0-17.html.
In related news, Director Masaharu Tanaka sold 20,747 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $24.21, for a total value of $502,284.87. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 53.00% of the stock is currently owned by insiders.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.